Teva, which is looking to close a $40 billion-plus deal for the generics arm of rival Allergan, struck a pair of divestment deals over the past couple of weeks. But it didn’t stop there.
On Tuesday, Impax Laboratories announced that it, too, was getting in on the action. The Hayward, CA-based company agreed to pay $586 million for a bundle of Teva’s assets.
With the transaction, Impax will grab a range of the Israeli drugmaker’s products, which span various stages of development and regulatory progress. It’s set to pick up 15 already marketed generics, plus three others close to market–one approved generic and two approved dosages of a currently marketed product that haven’t yet launched. The deal also covers one copycat med and another dosage of a currently marketed drug, both awaiting the FDA’s green light. And then there are full commercial rights to Impax’ own pending app for a knockoff of Johnson & Johnson’s ADHD med Concerta, on which it had previously partnered with Teva, and one generic candidate still in development.
It’s a significant get for Impax, which will soon be the proud owner of a portfolio that generated $150 million in 2015 net sales and about $100 million in gross profit last year.
And Teva’s hoping it’s a significant step toward closing a deal that has garnered serious antitrust scrutiny since it was announced last summer. Already this month, the Petah Tivka-based drugmaker has agreed to sell off 5 unapproved generics to Schaumburg, IL’s Sagent Pharmaceuticals, as well as a basket of 8 meds to India’s Dr. Reddy’s ($RDY) for $350 million.
Missing from the party, though, has been Mylan, despite analyst predictions that it would score more products as Teva pruned its lineup. Last November, Mylan lost out on a hostile quest for Ireland’s Perrigo–which some speculate began as an effort to ward off its own hostile suitor, Teva.
But while Mylan may not have snapped up any of Teva’s castoffs, it’s still been active at the M&A table. It recently unveiled a $1 million accord to buy some topical skin treatments from Renaissance Acquisition Holdings, and back in February, it inked a $7.2 billion pact to buy Sweden’s Meda.
By Carly Helfand
Source: Fierce Pharma
The novel drug – named Cobenfy – introduces a new mechanism of action to the schizophrenia treatment landscape by targeting cholinergic receptors as opposed to dopamine receptors. The market for schizophrenia drugs has long been dominated by dopamine-blocking antipsychotics, which are associated with significant side effects such as Parkinsonian symptoms, sexual dysfunction, and weight gain.
The European Commission (EC) has granted marketing authorisation to Leo Pharma’s Anzupgo (delgocitinib) cream for treating adults with moderate to severe chronic hand eczema (CHE). The cream is indicated for use in CHE patients for whom topical corticosteroids are not suitable.
After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi. Quigley will start Sept. 30 as the French Big Pharma’s chief scientific officer and global head of research, Sanofi told Fierce Biotech in an emailed statement.
